▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #150 by analyst upside · 2026-09-27
GOSS
Gossamer Bio, Inc.
Healthcare · Market Cap $67M · P/E 0x
ANALYST PRICE TARGET
+653.9%
implied upside to consensus target
Current Price $10.94
Consensus Target $82.48
Bull Target $120.0
Bear Target $22.4
Analysts Covering 5
ANALYST CONSENSUS - HOLD
Strong Buy
1
Buy
1
Hold
2
Sell
1
52-Week Low $9.12
52-Week High $309.6
YTD Return -95.3%
FUNDAMENTALS
Market Cap $67M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-52.73
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $53M
Profit Margin -235.0%
52-WEEK RANGE
52-Week Low $9.12
52-Week High $309.6
Current Price $10.94
Bear Target $22.4
Bull Target $120.0
● Now $10.94 ● Target $82.48
TRADING DATA
Avg Volume 360K
YTD Return -95.3%
Analyst Count 5
Consensus Hold
Upside to Target +653.9%
Last Updated 2026-09-27

ANALYST SUMMARY

Gossamer Bio, Inc. (GOSS) is currently trading at $10.94 with a Wall Street consensus price target of $82.48, implying potential upside of 653.9% over the next 12 months. 5 analysts currently cover GOSS, with a consensus rating of Hold - 40% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $120.0, while the most cautious has a target of $22.4.

GOSS operates in the Healthcare sector with a market capitalisation of $67M. The stock is down 95.3% year-to-date and is currently trading near the lower end of its 52-week range of $9.12 – $309.6.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for GOSS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Buy → Buy 2026-09-21 31% win rate (48 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-08-14 14% win rate (7 calls)
Leerink Partners ↑ Upgrade
Market Perform → Outperform 2026-07-28 29% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-07-27 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-25 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-26 31% win rate (48 calls)
Barclays - Reiterated
Underweight → Underweight 2026-05-19 Building track record
Cantor Fitzgerald ↓ Downgrade
Overweight → Neutral 2026-03-23 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
21
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →